Weight-loss Drug Successful in Experiments
A recent research study reveals that a weight-loss tablet named Qnexa helped patients lose about 22 pounds in a year and lowered their blood pressure and cholesterol numbers. Qnexa combines two medicines: one is phentermine, the most popular weight-loss medication in the U.S., and the other is topiramate (Topamax), which is used to treat migraine and epilepsy. The study was financed by Vivus, the company which makes Qnexa.
Recently, the Food and Drug Administration refused approval for Qnexa because of lack of data regarding its side effects. A recent study had found that topiramate can increase the risk of cleft palate/lip in infants born to mothers who used the drug.
In the Qnexa study, researchers found the drug also lowered blood sugar levels and triglycerides, which is a blood fat. The researchers say Qnexa is ideal for overweight and obese people whose health is being affected by their extra weight.
There were side effects too such as dry mouth, constipation, distorted taste, dizziness and insomnia. There was also a higher risk of anxiety and depression in people who took a higher dose of Qnexa. Health experts say the weight loss effect may cease if people stop using the drug. Vivus aims to resubmit Qnexa for FDA approval later this year.